Drugs / LIPO-202
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03005717 | Dec 2016 → Jun 2017 | — | Neothetics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02568319 | Sep → Dec 2015 | abdominal wall malformation | Neothetics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02397525 | Mar 2015 → Jun 2016 | abdominal wall malformation | Neothetics, Inc | Unknown | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02483533 | Jun → Dec 2015 | diastasis recti and weakness of the linea alba | Evofem Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02398188 | Apr → Oct 2015 | abdominal wall malformation | Evofem Inc. | Completed | Missed primary |
| Phase 3 | NCT02397499 | Apr → Dec 2015 | — | Neothetics, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIPO-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02483533 ↗ |
| Route | Subcutaneous | “treated with up to 30 subcutaneous injections of the assigned study drug into submental fat” NCT03005717 ↗ |